JP2016537345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537345A5 JP2016537345A5 JP2016529901A JP2016529901A JP2016537345A5 JP 2016537345 A5 JP2016537345 A5 JP 2016537345A5 JP 2016529901 A JP2016529901 A JP 2016529901A JP 2016529901 A JP2016529901 A JP 2016529901A JP 2016537345 A5 JP2016537345 A5 JP 2016537345A5
- Authority
- JP
- Japan
- Prior art keywords
- mtor inhibitor
- low
- use according
- mtor
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 70
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 70
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical group C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 22
- 229960005167 everolimus Drugs 0.000 claims description 22
- 230000001965 increasing effect Effects 0.000 claims description 22
- 230000002434 immunopotentiative effect Effects 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 18
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 15
- 239000012642 immune effector Substances 0.000 claims description 12
- 229940121354 immunomodulator Drugs 0.000 claims description 12
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 10
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims description 7
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 6
- 108091012583 BCL2 Proteins 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 6
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 6
- 102100033467 L-selectin Human genes 0.000 claims description 6
- 230000003281 allosteric effect Effects 0.000 claims description 6
- 229940043355 kinase inhibitor Drugs 0.000 claims description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 5
- 239000003060 catalysis inhibitor Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 5
- 229960002930 sirolimus Drugs 0.000 claims description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229950006418 dactolisib Drugs 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 69
- 239000000427 antigen Substances 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000012646 vaccine adjuvant Substances 0.000 description 4
- 229940124931 vaccine adjuvant Drugs 0.000 description 4
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361903636P | 2013-11-13 | 2013-11-13 | |
| US61/903,636 | 2013-11-13 | ||
| US201462027121P | 2014-07-21 | 2014-07-21 | |
| US62/027,121 | 2014-07-21 | ||
| US201462052629P | 2014-09-19 | 2014-09-19 | |
| US62/052,629 | 2014-09-19 | ||
| US201462076142P | 2014-11-06 | 2014-11-06 | |
| US62/076,142 | 2014-11-06 | ||
| PCT/US2014/065408 WO2015073644A1 (en) | 2013-11-13 | 2014-11-13 | Mtor inhibitors for enhancing the immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009002A Division JP2020097589A (ja) | 2013-11-13 | 2020-01-23 | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016537345A JP2016537345A (ja) | 2016-12-01 |
| JP2016537345A5 true JP2016537345A5 (enExample) | 2017-12-21 |
Family
ID=53057999
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529901A Withdrawn JP2016537345A (ja) | 2013-11-13 | 2014-11-13 | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| JP2020009002A Withdrawn JP2020097589A (ja) | 2013-11-13 | 2020-01-23 | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020009002A Withdrawn JP2020097589A (ja) | 2013-11-13 | 2020-01-23 | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150140036A1 (enExample) |
| EP (1) | EP3068435A1 (enExample) |
| JP (2) | JP2016537345A (enExample) |
| KR (1) | KR20160084438A (enExample) |
| CN (1) | CN105899232A (enExample) |
| AU (3) | AU2014348657A1 (enExample) |
| BR (1) | BR112016010716A8 (enExample) |
| CA (1) | CA2929181A1 (enExample) |
| EA (1) | EA201690987A1 (enExample) |
| MX (1) | MX2016006316A (enExample) |
| TW (1) | TWI679976B (enExample) |
| WO (1) | WO2015073644A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
| CA2859385A1 (en) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| WO2013158664A2 (en) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
| EA201690987A1 (ru) | 2013-11-13 | 2016-10-31 | Новартис Аг | Низкодозовые иммуностимулирующие ингибиторы mtor и их применения |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| EP3180359A1 (en) | 2014-08-14 | 2017-06-21 | Novartis AG | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| US20170252335A1 (en) * | 2014-10-17 | 2017-09-07 | Novartis Ag | Combination of Ceritinib with an EGFR Inhibitor |
| WO2016064683A1 (en) | 2014-10-24 | 2016-04-28 | St. Jude Children's Research Hospital | Coordinated metabolic reprogramming in response to productive viral infections |
| WO2016066608A1 (en) * | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| MX376083B (es) * | 2015-06-04 | 2025-03-07 | Pfizer | Formas de dosificacion solidas de palbociclib. |
| JP2018522028A (ja) * | 2015-07-31 | 2018-08-09 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の組み合わせ及びそれらの使用 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| WO2017053222A1 (en) * | 2015-09-24 | 2017-03-30 | Drexel University | Novel compositions and methods for treating or preventing dermal disorders |
| US10724095B2 (en) * | 2015-12-16 | 2020-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections |
| CN105816437B (zh) | 2016-03-29 | 2018-08-03 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| KR101796684B1 (ko) * | 2016-05-19 | 2017-11-10 | 건국대학교 산학협력단 | 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법 |
| KR102475256B1 (ko) * | 2016-09-28 | 2022-12-08 | 아브락시스 바이오사이언스, 엘엘씨 | 미토콘드리아 및 대사 장애를 치료하는 방법 |
| JP7467117B2 (ja) | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| JP2020500930A (ja) * | 2016-11-23 | 2020-01-16 | ノバルティス アーゲー | エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US10438189B2 (en) | 2017-02-22 | 2019-10-08 | Square, Inc. | Server-enabled chip card interface tamper detection |
| JP6482604B2 (ja) * | 2017-06-22 | 2019-03-13 | 教裕 南郷 | 外皮内溶解型ニードル及びニードル装置 |
| WO2019023181A1 (en) * | 2017-07-24 | 2019-01-31 | University Of Cincinnati | METHODS OF TREATING INFLUENZA-RELATED VIRAL PNEUMONIA |
| TWI795462B (zh) * | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
| MX2020005651A (es) * | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2020023533A1 (en) * | 2018-07-23 | 2020-01-30 | Translate Bio, Inc. | Dry power formulations for messenger rna |
| GB201813186D0 (en) * | 2018-08-13 | 2018-09-26 | Univ Central Lancashire | Solid dosage from production |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US12576069B2 (en) | 2019-09-11 | 2026-03-17 | Yale University | Compositions and methods for treating slow-flow vascular malformations |
| JP7805928B2 (ja) | 2019-11-26 | 2026-01-26 | ノバルティス アーゲー | Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用 |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| US20220079930A1 (en) * | 2020-02-04 | 2022-03-17 | Brain Cancer Research Institute | Therapeutic Cancer Immune Modulation by Treatment with mTOR Inhibitors |
| CN111214470A (zh) * | 2020-02-28 | 2020-06-02 | 北京澳丹斯生物科技有限公司 | 雷帕霉素及其衍生物在制备用于预防和治疗病毒引起的ade的药品的用途 |
| CN113679724B (zh) * | 2020-05-18 | 2023-04-07 | 中国科学院微生物研究所 | 一种流感病毒小分子抑制剂 |
| WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| TW202206093A (zh) * | 2020-08-12 | 2022-02-16 | 中國醫藥大學 | Ｓｅｍａ３ｄ拮抗劑用於預防或治療神經退化性疾病以及延長壽命之用途 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| US20240058349A1 (en) * | 2020-12-18 | 2024-02-22 | Northwestern University | Pi3k inhibitors for protection against glucocorticoid-induced atrophy |
| CN113082212A (zh) * | 2021-04-15 | 2021-07-09 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 包含mTOR抑制剂的药物组合物及其应用 |
| WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| WO2026060338A1 (en) * | 2024-09-13 | 2026-03-19 | Case Western Reserve University | Anticancer mtor activator |
| CN119215069A (zh) * | 2024-09-30 | 2024-12-31 | 广州百吉生物制药有限公司 | 一种用于清除衰老细胞的联合用药组合物及其应用 |
| WO2026080482A1 (en) * | 2024-10-07 | 2026-04-16 | Tornado Therapeutics, Inc. | Rapamycin derivatives and uses thereof |
| CN120789071A (zh) * | 2025-08-12 | 2025-10-17 | 北京大学 | Gpr68抑制剂在制备延缓衰老和/或治疗衰老相关性疾病的药物中的应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| GB2116183B (en) | 1982-03-03 | 1985-06-05 | Genentech Inc | Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it |
| ATE192037T1 (de) | 1989-12-29 | 2000-05-15 | Braun Medical Inc | Verwendung von arginin als immunstimulator |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| EP0729471A1 (en) | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| BR9408323A (pt) | 1993-12-17 | 1997-08-19 | Sandoz Ag | Derivados de rapamicina |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
| DE69624921T2 (de) | 1995-06-09 | 2003-09-11 | Novartis Ag, Basel | Rapamycinderivate |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| DK0920505T3 (da) | 1996-08-16 | 2008-09-08 | Schering Corp | Pattedyrcelleoverfladeantigener og tilhörende reagenser |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| CA2308114A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
| ATE376837T1 (de) | 1999-07-12 | 2007-11-15 | Genentech Inc | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
| IL147803A0 (en) | 1999-08-24 | 2002-08-14 | Ariad Gene Therapeutics Inc | 28-epirapalogs |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| GB0208104D0 (en) | 2002-04-09 | 2002-05-22 | Univ Dundee | Method |
| US20040106904A1 (en) | 2002-10-07 | 2004-06-03 | Gonnelli Robert R. | Microneedle array patch |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
| EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| AU2007230964B2 (en) * | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| US20090088373A1 (en) * | 2007-09-28 | 2009-04-02 | Gallo Richard L | Use of compositions to enhance innate immune response |
| JP2009084231A (ja) * | 2007-10-01 | 2009-04-23 | Stuetz Anton | 先天的免疫応答の増強のための組成物の使用 |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009104019A1 (en) | 2008-02-21 | 2009-08-27 | Astrazeneca Ab | Combination therapy 238 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2011526794A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＧＦ−βアンタゴニスト多重標的結合性分子 |
| AU2009279661A1 (en) * | 2008-08-05 | 2010-02-11 | Emory University | Use of mTOR inhibitors to enhance T cell immune responses |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CA2735456C (en) * | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| JPWO2010030002A1 (ja) | 2008-09-12 | 2012-02-02 | 国立大学法人三重大学 | 外来性ｇｉｔｒリガンド発現細胞 |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| AU2009313877A1 (en) * | 2008-11-13 | 2011-06-30 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic combination therapies and uses thereof |
| US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2375897A4 (en) * | 2009-01-14 | 2013-05-15 | Health Research Inc | METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| DK2414362T3 (da) | 2009-04-03 | 2014-09-22 | Verastem Inc | Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| JP2013539453A (ja) | 2010-07-09 | 2013-10-24 | エクセリクシス， インク． | 癌の治療のためのキナーゼ阻害物質の組み合わせ |
| US9062046B2 (en) | 2010-07-16 | 2015-06-23 | Piramal Enterprises Limited | Substituted imidazoquinoline derivatives as kinase inhibitors |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN103391780B (zh) * | 2011-02-16 | 2015-08-19 | 诺瓦提斯公司 | 用于治疗神经变性疾病的治疗剂的组合物 |
| WO2012148846A1 (en) * | 2011-04-25 | 2012-11-01 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| US20150065524A1 (en) | 2011-08-11 | 2015-03-05 | Intellikine Llc | Kinase inhibitor polymorphs |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| AU2013246443B2 (en) * | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| EA201690987A1 (ru) | 2013-11-13 | 2016-10-31 | Новартис Аг | Низкодозовые иммуностимулирующие ингибиторы mtor и их применения |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| BR112017000939A2 (pt) * | 2014-07-21 | 2017-11-14 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico de cll-1 |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| EP3712171A1 (en) * | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
-
2014
- 2014-11-13 EA EA201690987A patent/EA201690987A1/ru unknown
- 2014-11-13 BR BR112016010716A patent/BR112016010716A8/pt not_active IP Right Cessation
- 2014-11-13 US US14/540,867 patent/US20150140036A1/en not_active Abandoned
- 2014-11-13 JP JP2016529901A patent/JP2016537345A/ja not_active Withdrawn
- 2014-11-13 MX MX2016006316A patent/MX2016006316A/es unknown
- 2014-11-13 EP EP14815965.0A patent/EP3068435A1/en not_active Ceased
- 2014-11-13 KR KR1020167015237A patent/KR20160084438A/ko not_active Withdrawn
- 2014-11-13 WO PCT/US2014/065408 patent/WO2015073644A1/en not_active Ceased
- 2014-11-13 TW TW103139447A patent/TWI679976B/zh not_active IP Right Cessation
- 2014-11-13 CN CN201480072942.9A patent/CN105899232A/zh active Pending
- 2014-11-13 CA CA2929181A patent/CA2929181A1/en not_active Abandoned
- 2014-11-13 AU AU2014348657A patent/AU2014348657A1/en not_active Abandoned
-
2016
- 2016-10-12 US US15/292,088 patent/US10004803B2/en not_active Expired - Fee Related
-
2017
- 2017-10-12 AU AU2017245411A patent/AU2017245411B2/en not_active Ceased
-
2018
- 2018-06-25 US US16/017,173 patent/US10286069B2/en not_active Expired - Fee Related
-
2019
- 2019-03-22 US US16/361,822 patent/US20200054742A1/en not_active Abandoned
- 2019-10-10 AU AU2019246853A patent/AU2019246853A1/en not_active Abandoned
-
2020
- 2020-01-23 JP JP2020009002A patent/JP2020097589A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102646764B1 (ko) | 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도 | |
| Weeratna et al. | TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848) | |
| JP2017528433A5 (enExample) | ||
| JP2020183407A (ja) | Ｈｉｖを治療するためのトール様受容体の調節因子 | |
| JP2019517549A5 (enExample) | ||
| JP2018527366A (ja) | ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター | |
| Berdeja et al. | Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM) | |
| Mirandola et al. | Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis | |
| CN113874491A (zh) | Nk细胞培养基用添加剂组合物、使用该添加剂组合物的nk细胞培养方法及由此获得的改善皮肤问题用化妆品组合物 | |
| PH12013500581A1 (en) | Pharmaceutical combinations | |
| US20210030741A1 (en) | Pharmaceutical combination of everolimus with dactolisib | |
| JP2018529747A5 (enExample) | ||
| WO2020092650A1 (en) | Compositions and methods for modulating t cell exhaustion | |
| JP2024512558A5 (enExample) | ||
| JP2017512801A5 (enExample) | ||
| US20140011790A1 (en) | Methods and materials for reducing supression of immune function | |
| JP2022534494A5 (enExample) | ||
| CN110494137B (zh) | 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途 | |
| RU2019136781A (ru) | Способ лечения и схема клинического исследования географической атрофии, вызванной возрастной макулярной дегенерацией | |
| CN104338129B (zh) | 雷帕霉素作为疫苗佐剂的用途及制备方法 | |
| EP3681538A1 (en) | A3 adenosine receptor ligand for managing cytokine release syndrome | |
| Tanwar et al. | A novel in vivo adjuvant activity of hydrocarbon isolated from Hippophae rhamnoides: H. Tanwar et al. | |
| Katz et al. | Tanezumab, an Anti-Nerve Growth Factor (NGF) antibody, for the treatment of chronic low back pain (CLBP)–a randomized, controlled, double-blind, phase 2 trial | |
| Bharty et al. | Initiation of MDR TB treatment: Is hospitalization worth? | |
| WO2026025003A1 (en) | Non-invasive method for enhancing immune and t cell function using low intensity vibration |